Portfolio Companies

Invested in innovative therapies

A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on serious illness. They are focused on tackling the next frontier in cancer treatment, solid tumors.

Allakos, Inc. (NASDAQ: ALLK) is a clinical-stage company developing antibodies that target receptor molecules present on the surface of immune effector cells involved in allergy, inflammation, tissue damage and proliferative disorders.

Aravive, Inc. (NASDAQ:  ARAV) is developing treatments designed to halt progression of life-threatening diseases, including cancer and fibrosis.

Atreca, Inc. (NASDAQ:  BCEL) is a biopharmaceutical company developing novel therapeutics based on a deep understanding of the human immune response.

Autobahn Labs accelerates the translation of novel science to realize the potential of academic research. 

Our mission is to improve life health for people affected by CNS disorders by driving the regenerative power of the human body

Chinook Therapeutics, Inc. is a biotechnology company developing precision medicines for kidney diseases.

Delfi is developing a revolutionary test using DNA in the blood for early detection of cancer.  The ultimate target audience are doctors and their patients who will need this testing.

Dewpoint Therapeutics is developing a drug platform that targets biomolecular condensates, to pave the way for new approaches to treating the toughest diseases.

Elevatebio is creating and operating a portfolio of cell and gene therapy companies to develop, manufacture and commercialize life-transforming medicines.

Formerly known as Ervaxx, Enara Bio is a science-led company targeting the T-cell/cancer cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population.

Forma Therapeutics (NASDAQ:  FMTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers.

Genalyte delivers rapid, actionable results to physicians through decentralized laboratory testing, backed by remote Telehealth oversight and monitoring.

Hookipa Pharma, Inc. (NASDAQ:  HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on a proprietary arenavirus platform.

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry.

Ionpath, Inc. has developed a mass spectrometry based imaging platform that permits 50+ biomolecules (proteins, DNA, RNA) to be measured simultaneously on a single tissue selection with resolution surpassing light microscopy.

IVERIC bio (NASDAQ:  ISEE) is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs.

Levo Therapeutics, Inc. is dedicated to advancing treatments for Prader-Willi syndrome and related disorders.

MiroBio developing novel, best-in-class therapeutics that bring significant benefits to patients suffering from a range of auto-immune diseases.

Nalo, Inc. has a description that is just a placeholder for now. Then innovate products and services to improve the lives of patients suffering diseases.

Neurogene, Inc. is accelerating development of new genetic medicines to people with devastating neurological diseases.

Nkarta Therapeutics seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to the broad population of patients with a variety of hematologic and solid tumor malignancies.

Nura, AKA:  Proneurotech, is aspiring to develop disease modifying therapeutics to improve the lives of patient and families struggling with neurodegenerative disorders.

Odonate, Inc. (NASDAQ: ODT) is dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer.

Omniox, Inc. is an IND-stage biotherapeutics company developing breakthrough H-NOX platform technology into first-in-class and best-in-class OMX oxygen delivery vehicles that treat a range of significant unmet medical needs.

Palvella Therapeutics is a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for serious genetic diseases with no approved treatments.

Principia Biopharma, Inc. (NASDAQ: PRNB) is a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology.

SpringWorks, Inc. (NASDAQ:  SWTX) is a clinical-stage biopharmaceutical company that identifies and advances promising science and pioneers efficient pathways for drug development for patients with severe rare diseases and cancer.

Sutro Biopharma (NASDAQ: STRO) is a clinical stage company focusing primarily on next generation cancer and autoimmune therapeutics.

 Synthekine is a biotechnology company focused on discovery and developing best in class cytokine therapeutics.

Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is advancing a new wave of medicines to control the expression of disease-driving genes.

Velicept Therapeutics, Inc. is a clinical development company focused on advancing best-in-class compounds with the potential to fill unmet medical needs.